Julie Jacobs

12PUBLICATIONS
37CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityBiomedical instrumentationHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Mar 27, 2023
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer.

Tal Flieswasser, Astrid Van den Eynde, Laurie Freire Boullosa

|Nov 02, 2021
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.

Nicolas Leupin, Pier Luigi Zinzani, Franck Morschhauser

|Jun 21, 2020
Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer.

Tal Flieswasser, Jinthe Van Loenhout, Laurie Freire Boullosa

|Apr 08, 2020
Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients.

Eline Berghmans, Julie Jacobs, Christophe Deben

|Dec 16, 2019
Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions.

Laure Sorber, Karen Zwaenepoel, Julie Jacobs

|Dec 05, 2019
Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status.

Jolien Van den Bossche, Andreas Domen, Marc Peeters

Pageof 2

Frequent Collaborators

7 joint publications

Evelien Smits

5 joint publications

Filip Lardon

4 joint publications

Christophe Deben

3 joint publications

Christian Rolfo